Newmont Mining Corp(NYSE:NEM) shares gained 0.25% to $27.85. Jefferies Group lowered shares of Newmont Mining from a hold rating to an underperform rating in a report released on July 4. Additionally, analysts at Credit Suisse reiterated a hold rating on shares of Newmont Mining Corp. in a research note to investors on June 26. They now have a $32.00 price target on the stock.
Banco Santander (Brasil) SA(ADR)(NYSE:BSBR) shares fell 0.34% to $5.80. The company on May 13 announced that following the announcements made on February 22, 2011 and July 14, 2011, in relation to the sale of the total shares of its wholly owned subsidiary Zurich Santander Brasil Seguros e Previdencia SA (current name Santander Seguros SA) (Zurich Santander Seguros) to Zurich Santander Insurance America SL (current name of ZS Insurance America SL), a holding company located in Spain whose 51% stake is held by Zurich Financial Services Ltd and its affiliated companies and 49% by Banco Santander SA, the Company’s controlling shareholder, the total value of the transaction was of BRL 2,744,990,429.98 resulting in a price reduction of BRL 6,567,142.00.
Chimera Investment Corporation (NYSE:CIM) shares declined 0.71% to $2.80. The Board of Directors of Chimera Investment on June 19 declared the second quarter 2013 common stock cash dividend of $0.09 per common share. This dividend is payable July 31, 2013, to common shareholders of record on July 1, 2013. The ex-dividend date is June 27, 2013.
As previously announced, the Company initiated a regular quarterly dividend of $0.09 per common share for each of the quarters in 2013, portions of which may be ordinary income, capital gains or a return of capital. The Board of Directors will review this program after the conclusion of the fourth quarter of 2013.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares decreased 3.81% to $20.49. Guggenheim assumed coverage on shares of CLDX in a research note issued to investors on July 5. The firm issued a buy rating and a $24.00 price target on the stock.
Additionally, the company on July 1 reported that the first patient has been dosed in the Company’s pilot study of CDX-1135 (a soluble form of human complement receptor type 1) in dense deposit disease (DDD). DDD is an ultra-rare, progressive kidney disease that ultimately results in kidney failure in the majority of affected individuals.